Eli Lilly's Retatrutide Hits All Endpoints in Phase 3 Type 2 Diabetes Trial
Retatrutide met its primary endpoint of superior A1C reduction and all key secondary endpoints at 40 weeks compared with placebo in type 2 diabetes patients, also demonstrating significant weight loss.